Allogeneic hematopoietic cell transplantation for plasma cell myeloma can lead to graft-vs-myeloma immunity and long-term survivorship, but limited efficacy and associated toxicities have prevented its widespread use. So called immunomodulatory agents such as thalidomide, lenalidomide, and pomalidomide have revolutionized the therapy for myeloma, improving response and survival but relapses remain common. This session will focus on the emerging targeted and potent immunotherapies for myeloma that may synergize with other therapies and markedly improve outcome for the disease. Preliminary clinical results demonstrate activity in even heavily treated patients with a manageable toxicity profile. Immunotherapy is therefore rapidly becoming an integral component of myeloma therapy and promises to remain so for the foreseeable future.
Dr. Weber will summarize the rationale and clinical impact of recently FDA approved monoclonal antibody therapy in myeloma (ant-CD38, anti-SLAMF7/CS1) and the best timing of the introduction of these agents into the continuum of care for this disease. She will also consider optimal combinations with other agents and new potential targets in development.
Dr. Stadtmauer will discuss the emerging strategies for cellular immunotherapy for myeloma including Chimeric Antigen Receptor (CAR), T-Cell Receptor (TCR), and Marrow Infiltrating Lymphocyte (MIL) engineered T cells, as well as vaccine approaches.
Dr. Benson will review how the new inhibitors of programmed death T-cell regulatory pathways (PD-1 inhibitors and others) may synergize with other therapies for myeloma and lead to improved response and survival.